
Clinical Practice Guidelines in Oncology

Crystal S. Denlinger, MD; Jennifer A. Ligibel, MD; Madhuri Are, MD; K. Scott Baker, MD, MS; Wendy Demark-Wahnefried, PhD, RD; Debra L. Friedman, MD, MS; Mindy Goldman, MD; Lee Jones, PhD; Allison King, MD; Grace H. Ku, MD; Elizabeth Kvale, MD; Terry S. Langbaum, MAS; Kristin Leonardi-Warren, RN, ND; Mary S. McCabe, RN, BS, MS; Michelle Melisko, MD; Jose G. Montoya, MD; Kathi Mooney, RN, PhD; Mary Ann Morgan, PhD, FNP-BC; Javid J. Moslehi, MD; Tracey O’Connor, MD;

Pain in Survivors

More than one-third of posttreatment cancer survivors experience chronic pain, which often leads to psychological distress; decreased activity, motivation, and personal interactions; and an overall poor quality of life.1–5 Pain in survivors is often ineffectively managed. Barriers to optimal pain management in cancer survivors include health care providers’ lack of training, fear of side effects and addiction, and reimbursement issues.6

Pain has 2 predominant mechanisms: nociceptive and neuropathic.7,8 Injury to somatic and visceral struc-

Please Note

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way. The full NCCN Guidelines for Survivorship are not printed in this issue of JNCCN but can be accessed online at NCCN.org.

© National Comprehensive Cancer Network, Inc. 2014. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

Disclosures for the NCCN Survivorship Panel

At the beginning of each NCCN Guidelines panel meeting, panel members review all potential conflicts of interest. NCCN, in keeping with its commitment to public transparency, publishes these disclosures for panel members, staff, and NCCN itself.

Individual disclosures for the NCCN Survivorship Panel members can be found on page 500. (The most recent version of these guidelines and accompanying disclosures are available on the NCCN Web site at NCCN.org.)

These guidelines are also available on the Internet. For the latest update, visit NCCN.org.

© JNCCN—Journal of the National Comprehensive Cancer Network | Volume 12 Number 4 | April 2014
Survivorship
NCCN Guidelines®
© JNCCN—Journal of the National Comprehensive Cancer Network | Volume 12 Number 4 | April 2014

Survivorship

Screening for and Assessment of Pain

All cancer survivors should be screened for pain at regular intervals. If pain is present, the intensity should be quantified by the survivor. Because pain is inherently subjective, self-report of pain is the current standard of care for assessment. Intensity of pain should be quantified using a 0 to 10 numeric rating scale, a categoric scale, or a pictorial scale (eg, Wong-Baker FACES Pain Rating Scale).9–12 In addition, the survivor should be asked to describe the characteristics of the pain (eg, aching, burning). Severe uncontrolled pain is a medical emergency and should be responded to promptly. An oncologic emergency also should be ruled out in these cases.

A comprehensive evaluation, as outlined in the NCCN Guidelines for Adult Cancer Pain (available at NCCN.org), is essential to ensure proper pain management. The cause and pathophysiology of the pain should be identified to determine the optimal

Text cont. on page 496.
If pain present

- Quantify pain intensity and characterize quality
  - See "Pain Intensity Rating" (PAIN-A) in the NCCN Guidelines for Adult Cancer Pain*
- Severe uncontrolled pain is a medical emergency and should be responded to promptly
  - Rule out oncologic emergency

If no pain

Screen for cancer pain or cancer treatment-related pain at regular intervals

Anticipated painful events and procedures

Rescreen at each subsequent visit

See "Procedure-Related Pain and Anxiety" (PAIN-B) in the NCCN Guidelines for Adult Cancer Pain*

*To view the most recent version of these guidelines, visit NCCN.org.

<table>
<thead>
<tr>
<th>CANCER PAIN SYNDROME</th>
<th>TREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>* General measures:</td>
<td></td>
</tr>
<tr>
<td>▶ Adjuvant analgesics</td>
<td></td>
</tr>
<tr>
<td>(See PAIN-G from the NCCN Guidelines for Adult Cancer Pain*)</td>
<td></td>
</tr>
<tr>
<td>▶ Antidepressants</td>
<td></td>
</tr>
<tr>
<td>▶ Anticonvulsants</td>
<td></td>
</tr>
<tr>
<td>▶ Corticosteroids</td>
<td></td>
</tr>
<tr>
<td>▶ Opioids*</td>
<td></td>
</tr>
<tr>
<td>(See PAIN-3, PAIN-4, and PAIN-5 in the NCCN Guidelines for Adult Cancer Pain*)</td>
<td></td>
</tr>
<tr>
<td>▶ Cognitive behavior therapy and psychosocial support</td>
<td></td>
</tr>
<tr>
<td>(See PAIN-H from the NCCN Guidelines for Adult Cancer Pain*)</td>
<td></td>
</tr>
<tr>
<td>▶ Consider hypnosis</td>
<td></td>
</tr>
<tr>
<td>▶ For refractory pain, consider referral to pain management services, interventional specialist, physical therapy, physical medicine, and/or rehabilitation</td>
<td></td>
</tr>
<tr>
<td>▶ Consider dorsal column stimulation</td>
<td></td>
</tr>
<tr>
<td>▶ Local therapies</td>
<td></td>
</tr>
<tr>
<td>▶ Pharmacologic therapies</td>
<td></td>
</tr>
<tr>
<td>▶ Topical patches (lidoderm, capsaicin)</td>
<td></td>
</tr>
<tr>
<td>▶ Creams (ketamine and amitriptyline combined)</td>
<td></td>
</tr>
<tr>
<td>▶ Intercostal nerve blocks</td>
<td></td>
</tr>
<tr>
<td>▶ Nonpharmacologic therapies</td>
<td></td>
</tr>
<tr>
<td>▶ Heat</td>
<td></td>
</tr>
<tr>
<td>▶ Ice</td>
<td></td>
</tr>
<tr>
<td>▶ Acupuncture</td>
<td></td>
</tr>
</tbody>
</table>

*To view the most recent version of these guidelines, visit NCCN.org.

\*See Principles of Opioid Use in Long-Term Survivors (SPAIN-A).
### CANCER PAIN SYNDROME

| Specific postoperative pain syndromes b | • For postamputation syndrome:  
  ➤ Physical therapy for desensitization  
  ➤ Cognitive therapy  
  ➤ Upper extremities: consider stellate ganglion block  
  ➤ Lower extremities: consider lumbar sympathetic block  
  ➤ Neuromas: consider phenol/alcohol block  
• For postradical neck dissection syndrome:  
  Physical therapy for stretching, range of motion  
  ➤ Myofascial release  
  ➤ Soft tissue massage  
  ➤ Trigger point injections  
  ➤ Possible botulinum toxin injection  
  ➤ For postmastectomy syndrome:  
  ➤ Intercostal nerve block  
  ➤ TENS unit  

| • General measures:  
  ➤ Adjuvant analgesics  
  See PAIN-G in the NCCN Guidelines for Adult Cancer Pain*  
  ➤ Psychosocial support and behavioral interventions  
  See PAIN-H in the NCCN Guidelines for Adult Cancer Pain*  
  ➤ Opioids a  
  See PAIN-3, PAIN-4, and PAIN-5 in the NCCN Guidelines for Adult Cancer Pain*  
  • For refractory pain, consider referral to pain management services, interventional specialist, physical therapy, physical medicine and/or rehabilitation  
  ➤ Consider transcutaneous electrical nerve stimulation (TENS) unit  
  ➤ Consider dorsal column stimulation  
  ➤ Intercostal nerve blocks  
  ➤ Neurotomy with radiofrequency ablation  |

| | • For postamputation syndrome:  
  ➤ Physical therapy for desensitization  
  ➤ Cognitive therapy  
  ➤ Upper extremities: consider stellate ganglion block  
  ➤ Lower extremities: consider lumbar sympathetic block  
  ➤ Neuromas: consider phenol/alcohol block  
• For postradical neck dissection syndrome:  
  Physical therapy for stretching, range of motion  
  ➤ Myofascial release  
  ➤ Soft tissue massage  
  ➤ Trigger point injections  
  ➤ Possible botulinum toxin injection  
  ➤ For postmastectomy syndrome:  
  ➤ Intercostal nerve block  
  ➤ TENS unit  

---

*To view the most recent version of these guidelines, visit NCCN.org.

aSee Principles of Opioid Use in Long-Term Survivors (SPAIN-A).

bThere are other postoperative pain syndromes and many treatment measures can be used across syndromes. Also consider referral to appropriate specialist.

SPAIN-3

CANCER PAIN SYNDROME TREATMENT

- Nonpharmacologic
  - Exercise
  - Heat (paraffin wax, hot pack)
  - Cold pack
  - Physical therapy
  - Aquatic therapy
  - Ultrasonic stimulation
  - Massage
  - Acupuncture
- Pharmacologic
  - Nonsteroidal anti-inflammatory drugs (NSAIDs)
  - Muscle relaxants
  - Antiepileptic drugs (gabapentin, pregabalin)
  - Serotonin-norepinephrine reuptake inhibitors (SNRIs)
  - Tricyclic antidepressants (TCAs)
- Consider referral to pain management services, interventional specialist, physical therapy, physical medicine, and/or rehabilitation

- For vertebral compression:
  - General measures:
    - Vitamin D
    - NSAIDs
    - Muscle relaxants
    - Consider vertebral augmentation (vertebroplasty, kyphoplasty)
  - Consider referral to pain management services, interventional specialist, physical therapy, physical medicine, and/or rehabilitation
  - For acute vertebral compression:
    - Opioids
    - Bracing (thoracolumbar sacral orthosis [TLSO], Jewett brace)
    - Limited bedrest
    - Weight-bearing exercises when pain improves
    - Physical therapy
  - For chronic vertebral compression:
    - Weight-bearing exercises
    - Physical therapy: thoracic and lumbar stabilization exercises
- For avascular necrosis:
  - Physical therapy: based on weight-bearing and range-of-motion restrictions
  - Opioids
  - Muscle relaxants if myofascial component
  - Cement augmentation for fractures
- For osteonecrosis of the jaw:
  - Anticonvulsants
  - SNRIs
  - Opioids
  - Consider referral to oral surgeon

---

*See Principles of Opioid Use in Long-Term Survivors (PAIN-A).

‡Ultrasonic stimulation is a type of heat treatment that can penetrate directly to the bone and should be used with caution. It is not recommended for patients with multiple myeloma or bone metastases.

§For skeletal metastases and/or bone pain, see PAIN-D in the NCCN Guidelines for Adult Cancer Pain (to view the most recent version of these guidelines, visit NCCN.org).
# Survivorship: Pain, Version 1.2014

Clinical trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise indicated.

## Cancer Pain Syndrome

### Myofascial Pain
- For rotator cuff tendonitis/adhesive capsulitis:
  - Physical therapy
  - Range-of-motion exercises
  - Strengthening shoulder stabilizers
  - Soft tissue/myofascial release massage
- Acupuncture or acupressure
- Ultrasonic stimulation
- NSAIDs
- Local injections to intra-articular joint
- For neck/back pain:
  - Nonpharmacologic
  - Physical therapy for neck/lumbar stabilization and strengthening exercises
  - Massage
  - Ultrasonic stimulation
  - Acupuncture or acupressure
- Pharmacologic
  - Topical ointments (ketamine)
  - NSAIDs
  - Antiepileptic drugs
  - SNRIs
  - Local measures (Lidoderm or capsaicin patches)
  - Trigger point injections
  - Epidural steroid injections
  - Radiofrequency ablation
  - Dorsal column stimulation for intractable cases
- For muscle cramps, spasms
  - Massage
  - Exercise
  - Check electrolytes, calcium, magnesium levels
  - NSAIDs
  - Consider referral to pain management services, interventional specialist, physical therapy, physical medicine, and/or rehabilitation

### Gastrointestinal/Urinary/Pelvic Pain
- Consider referral to gastroenterologist
- For chronic pelvic pain:
  - Consider referral to physical therapy for pelvic floor strengthening exercises
  - Proper hydration
  - Bowel regimen
  - Dorsal column stimulation for chronic cystitis and chronic pelvic pain
  - Analgesics
  - For dyspareunia, see SSFF-2 (available online, in these guidelines, at NCCN.org)
  - Consider referral to pain management services, interventional specialist, physical therapy, physical medicine, and/or rehabilitation

### Lymphedema
- Compression garments
- Progressive resistance training with compression garments
- Physical therapy with range of motion
- Manual lymphatic drainage
- Consider referral to lymphedema specialist

---

*Ultrasonic stimulation is a type of heat treatment that can penetrate directly to the bone and should be used with caution. It is not recommended for patients with multiple myeloma or bone metastases.*

CANCER PAIN SYNDROME

Postradiation pain
- Pain may be acute or appear months after radiation
- Radiation may lead to scarring, adhesions, or fibrosis
  ▶ Differentiate fibrosis from recurrent tumor
- Radiation to a localized area of the body may cause a chronic pain syndrome in that area

TREATMENT

- Treat according to specific cancer pain syndrome guidelines, if appropriate (see SPAIN-1 for list of cancer pain syndromes)
- Physical therapy
- Pain medication
- Surgical lysis of adhesions may be indicated in extreme circumstances

PRINCIPLES OF OPIOID USE IN LONG-TERM SURVIVORS

- Use the lowest opioid dose possible, if opioids are necessary
- Functionality may be a better endpoint for measuring outcomes, rather than numerical rating of pain
- Reevaluate the effectiveness and necessity of opioids on a regular basis
  ▶ If there is no improvement in function, or if opioid-induced hyperalgesia is suspected, recommend gradual tapering of opioids to help avoid symptoms of withdrawal
  ▶ Discussion of gradual tapering should be routine
  ▶ Consider establishing pain treatment agreements (see PAIN-L in the NCCN Guidelines for Adult Cancer Pain; to view the most recent version of these guidelines, visit NCCN.org)
- Address medical-related issues caused by use of chronic or high-dose opioids
  ▶ Endocrine/hypopituitary abnormalities

SPAIN-9, SPAIN-A
therapeutic strategy. In addition, the survivor’s goals for comfort and function should be determined.

Management of Pain

The goals of pain management are to increase comfort, maximize function, and improve quality of life. A multidisciplinary approach is recommended, with a combination of pharmacologic treatments, psychosocial and behavioral interventions, physical therapy and exercise, and interventional procedures.2,13,14

The NCCN Survivorship Panel made recommendations for the management of 8 categories of cancer pain syndromes: neuropathic pain, chronic postoperative pain (ie, pain syndromes after amputation, neck dissection, mastectomy), myalgias/arthritis, skeletal pain, myofascial pain, gastrointestinal/urinary/pelvic pain, lymphedema, and postradiation pain. Neuropathic pain commonly results from some systemic anticancer agents.1 The incidence of chronic pain after surgical treatment varies with the type of procedure and is as high as 60% in patients treated with breast surgery and 50% in those treated with lung surgery.1 Arthralgias, characterized by joint pain and stiffness, occur in roughly half of women taking aromatase inhibitors as adjuvant therapy for breast cancer.15 Pelvic pain often occurs after pelvic radiation, resulting from fractures, fistulae, proctitis, cystitis, dyspareunia, or enteritis.1

Pharmacologic interventions, local therapies, psychosocial support and behavioral treatments, physical therapy and exercise, and interventional procedures are discussed. For more information about the management of cancer-related pain, please see the NCCN Guidelines for Adult Cancer Pain (to view the most recent version of these guidelines, visit NCCN.org). These guidelines include information on opioid use and pain treatment agreements for patients at risk for medication misuse or diversion; adjuvant analgesics; and psychosocial support and behavioral interventions that may be modified to fit the individual survivor’s circumstances.

Pharmacologic Interventions

Pharmacologic measures are the foundation of treatment of many of the common pain syndromes in survivors. Pharmacologic recommendations in these guidelines vary depending on the pain syndrome and include opioids, adjuvant analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), and muscle relaxants.2,16–18 Topical medications are discussed in “Local Therapies” (see page 497).

Opioids: Opioids may be recommended for the treatment of neuropathic, postoperative, and skeletal pain. Data on the long-term use of opioids in survivors are lacking.14,17,19

The NCCN Guidelines for Adult Cancer Pain (available at NCCN.org) recommend screening survivors for risk factors of aberrant opioid use or diversion of pain medication, using a detailed patient evaluation or tools such as the Screener and Opioid Assessment for Patients with Pain—Revised (SOAPP-R) or Opioid Risk Tool (ORT), before prescribing.20–24 In addition, if opioids are deemed necessary for any survivor (regardless of aberrant use risk level), the NCCN Survivorship Panel recommends using the lowest dose possible and reevaluating the effectiveness and necessity of opioids on a regular basis. Pain treatment agreements can also be considered.25

Adjuvant Analgesics: Adjuvant analgesics include antidepressants (eg, serotonin-norepinephrine reuptake inhibitors [SNRIs], tricyclic antidepressants), anticonvulsants (eg, gabapentin, pregabalin), and corticosteroids. These are recommended for the treatment of neuropathic and postoperative pain in survivors. The term adjuvant refers to the fact that they are often coadministered with an opioid to enhance analgesia or reduce the opioid requirement, but they may also be used as sole pain treatment. A recent systematic review found that antidepressants, anticonvulsants, other adjuvant analgesics, and opioids were all effective at reducing neuropathic pain in patients with cancer.17 Another review found that antidepressants and antiepileptics provide additional neuropathic pain relief when added to opioids in patients with cancer.26

Tricyclic antidepressants have been shown to relieve neuropathic pain in the noncancer setting.27,28 In addition, the SNRI duloxetine was recently shown to effectively reduce pain in a multinstitutional, randomized, double-blind, placebo-controlled crossover trial of 231 patients with painful chemotherapy-induced neuropathy.29

The most commonly used anticonvulsant drugs for the treatment of cancer-related pain, gabapentin and pregabalin, have primarily been studied in noncancer neuropathy syndromes.30,31 Only limited data support the effectiveness of corticosteroids for cancer-related pain, and these may also have anti-inflammatory effects.12–14

NSAIDs: NSAIDs are recommended for the treatment of myofascial and skeletal pain and for myalgias.
and arthralgias. NSAIDs are nonopioid analgesics that block the biosynthesis of prostaglandins, which are inflammatory mediators that initiate, cause, intensify, or maintain pain. A recent systematic review found that data supporting the use of NSAIDs for control of pain in patients with advanced cancer are limited and weak, but suggest some efficacy at reducing pain and opioid dose requirement.\textsuperscript{35}

A discussion of contraindications and safety precautions that should be considered before prescribing NSAIDs is provided in the NCCN Guidelines for Adult Cancer Pain (to view the most recent version of these guidelines, visit NCCN.org).

**Muscle Relaxants:** Muscle relaxants (eg, diazepam, lorazepam, metaxalone) reduce muscle spasm and are recommended for the treatment of skeletal pain, myalgias, and arthralgias. Evidence for their efficacy in providing pain relief in the noncancer settings is limited.\textsuperscript{36,37} No data could be found in the setting of cancer-related pain.

**Psychosocial Support and Behavioral Interventions**

Cognitive interventions are aimed at enhancing a sense of control over the pain or its underlying cause. Breathing exercises, relaxation, imagery or hypnosis, and other behavioral therapies can be very useful.\textsuperscript{3,38-43} Psychosocial support and education should also be provided.\textsuperscript{44} Some studies in patients with cancer suggest that psychosocial and behavioral interventions such as skills training, education, relaxation training, supportive-expressive therapy, and cognitive behavioral therapy may be effective at reducing pain.\textsuperscript{40,45} Hypnosis can also be considered for treatment of neuropathic pain. Overall, data support the benefit of hypnosis for controlling pain in cancer and other settings, but are lacking in the survivorship population.\textsuperscript{46}

In general, studies regarding psychosocial support and behavioral interventions for reducing pain in survivors are limited. A recent systematic review and meta-analysis assessed the efficacy of psychosocial interventions for treating pain in patients with breast cancer and survivors.\textsuperscript{47} Although results suggest an effect, more studies are clearly needed in the survivorship population.

**Physical Therapy and Exercise**

Physical therapy and general exercise may also be effective for the treatment of pain in survivors, with the main goal of increasing mobility.\textsuperscript{3,13,48,49} Several randomized controlled trials have reported a reduction of neck and shoulder pain associated with exercise or therapy programs.\textsuperscript{50-52} In one study, 52 survivors of head and neck cancer were randomized to a progressive-resistance exercise training (PRET) program or standard therapeutic exercise for 12 weeks.\textsuperscript{52} Pain scores decreased more dramatically in the PRET group ($P=.001$). In another study of 66 survivors of breast cancer, those randomized to an 8-week water exercise program experienced a greater reduction of neck and shoulder pain than those randomized to usual care.\textsuperscript{50} In addition, group exercise in the community, with trainers specifically trained to work with cancer survivors, has been shown to reduce pain and other symptoms.\textsuperscript{53}

**Local Therapies**

Local therapies, including heat, cold packs, massage, medicated creams, ointments, and patches, are recommended for the treatment of myalgias, arthralgias, and neuropathic and myofascial pain.\textsuperscript{3} Specifically, topical lidocaine, capsaicin, ketamine, and amitriptyline are recommended for treatment of some of the various cancer pain syndromes. Data are limited on the effectiveness of ketamine and amitriptyline,\textsuperscript{54-59} but the evidence for the effectiveness of lidocaine and capsaicin is stronger.\textsuperscript{54,56-58} In a randomized trial of 35 patients with non-cancer-related postherpetic, postoperative, or diabetes-related neuropathic pain, pain intensity was reduced with topical lidocaine but not with topical amitriptyline when compared with placebo.\textsuperscript{57} A larger trial with a similar population of 92 patients found no effect of topical amitriptyline, ketamine, or a combination of the two.\textsuperscript{60} Another study found that a higher dose of amitriptyline had some efficacy in reducing peripheral neuropathy, but also showed systemic effects.\textsuperscript{61} Lidocaine has been shown to reduce the severity of postherpetic neuropathy and cancer-related pain.\textsuperscript{62,63}

**Interventional Procedures**

Referral to pain management services for interventional procedures, including transcutaneous electrical nerve stimulation (TENS), intercostal nerve blocks, and dorsal column stimulation, is recommended for refractory pain in survivors. Data on the efficacy of these interventions are mainly from patients with active cancer or the noncancer setting.\textsuperscript{3,64} TENS is a noninvasive procedure with electrodes placed in or around the painful area.\textsuperscript{1} A recent sys-
tematic review found that data supporting the efficacy of TENS for reducing cancer-related pain are inconclusive.65

The goal of invasive interventions, such as an intercostal nerve block, is to interrupt nerve conduction by either destroying nerves or interfering with their function.3 The data on these interventions are also limited.3

**Acupuncture**

Acupuncture is recommended as an option for the treatment of myofascial pain in survivors. Evidence supporting the efficacy of this technique for reducing cancer-related pain is extremely limited.66,67

**References**


## Individual Disclosures for the NCCN Survivorship Panel

<table>
<thead>
<tr>
<th>Panel Member</th>
<th>Clinical Research Support/Data Safety Monitoring Board</th>
<th>Advisory Boards, Speakers Bureau, Expert Witness, or Consultant</th>
<th>Patent, Equity, or Royalty</th>
<th>Other</th>
<th>Date Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Madhuri Are, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>5/15/13</td>
</tr>
<tr>
<td>K. Scott Baker, MD, MS</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>11/22/13</td>
</tr>
<tr>
<td>Wendy Demark-Wahnefried, PhD, RD</td>
<td>National Cancer Institute; Harvest for Health Gardening Project for Breast Cancer Survivors; and Nutrigenomic Link between Alpha-Linolenic Acid and Aggressive Prostate Cancer</td>
<td>American Society of Clinical Oncology</td>
<td>None</td>
<td>American Society of Preventive Oncology</td>
<td>11/13/13</td>
</tr>
<tr>
<td>Crystal S. Denlinger, MD</td>
<td>Bayer HealthCare; ImClone Systems Incorporated; MedImmune Inc.; OncoMed Pharmaceuticals; Astex Pharmaceuticals; Merrimack Pharmaceuticals; and Pfizer Inc.</td>
<td>Eli Lilly and Company</td>
<td>None</td>
<td>None</td>
<td>1/9/14</td>
</tr>
<tr>
<td>Debra L. Friedman, MD, MS</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>5/26/13</td>
</tr>
<tr>
<td>Mindy Goldman, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Pending</td>
</tr>
<tr>
<td>Lee W. Jones, PhD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>2/2/12</td>
</tr>
<tr>
<td>Allison King, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>8/12/13</td>
</tr>
<tr>
<td>Grace H. Ku, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>8/13/13</td>
</tr>
<tr>
<td>Elizabeth Kvale, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>10/7/13</td>
</tr>
<tr>
<td>Terry S. Langbaum, MAS</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>8/13/13</td>
</tr>
<tr>
<td>Kristin Leonard-Lawrence, RN, ND</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>1/6/14</td>
</tr>
<tr>
<td>Jennifer A. Ligibel, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>10/3/13</td>
</tr>
<tr>
<td>Mary S. McCabe, RN, BS, MS</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>8/12/13</td>
</tr>
<tr>
<td>Michelle Melisko, MD</td>
<td>Celldex Therapeutics; and Galena Biopharma</td>
<td>Agendia BV; Genentech, Inc.; and Novartis Pharmaceuticals Corporation</td>
<td>None</td>
<td>None</td>
<td>10/11/13</td>
</tr>
<tr>
<td>Jose G. Montoya, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>12/6/13</td>
</tr>
<tr>
<td>Kathy Mooney, RN, PhD</td>
<td>University of Utah</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>9/30/13</td>
</tr>
<tr>
<td>Mary Ann Morgan, PhD, FNP-BC</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>8/19/13</td>
</tr>
<tr>
<td>Javid J. Moslehi, MD</td>
<td>None</td>
<td>ARIAD Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.</td>
<td>None</td>
<td>None</td>
<td>1/27/14</td>
</tr>
<tr>
<td>Tracey O’Connor, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>6/13/13</td>
</tr>
<tr>
<td>Linda Overholser, MD, MPH</td>
<td>None</td>
<td>Antigenics Inc.; and Colorado Central Cancer Registry Care Plan Project</td>
<td>None</td>
<td>None</td>
<td>10/10/13</td>
</tr>
<tr>
<td>Electra D. Paskett, PhD</td>
<td>Merck &amp; Co., Inc.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>6/13/13</td>
</tr>
<tr>
<td>Muhammad Raza, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>8/23/12</td>
</tr>
<tr>
<td>Karen L. Syrjala, PhD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>10/3/13</td>
</tr>
<tr>
<td>Susan G. Urba, MD</td>
<td>None</td>
<td>Eisai Inc.; and Helsinn Therapeutics (U.S.), Inc.</td>
<td>None</td>
<td>None</td>
<td>10/9/13</td>
</tr>
<tr>
<td>Mark T. Wakabayashi, MD, MPH</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>6/19/13</td>
</tr>
<tr>
<td>Phyllis Zee, MD</td>
<td>Philips/Respironics</td>
<td>Merck &amp; Co., Inc.; Jazz Pharmaceuticals; Vanda Pharmaceuticals; and Purdue Pharma LP</td>
<td>None</td>
<td>None</td>
<td>3/26/14</td>
</tr>
</tbody>
</table>

The NCCN Guidelines Staff have no conflicts to disclose.

© JNCCN—Journal of the National Comprehensive Cancer Network | Volume 12 Number 4 | April 2014